Min Steve T. 4
4 · VALEANT PHARMACEUTICALS INTERNATIONAL · Filed Oct 20, 2010
Insider Transaction Report
Form 4
Min Steve T.
EVP and General Counsel
Transactions
- Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−75,923→ 0 totalExercise: $17.11Exp: 2018-06-30→ Common Stock (75,923 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−83,955→ 0 totalExercise: $38.47Exp: 2017-03-03→ Common Stock (83,955 underlying) - Disposition to Issuer
Common Stock
2010-09-28−213,069→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-09-28−23,376→ 0 totalExercise: $17.11Exp: 2018-06-30→ Common Stock (23,376 underlying)
Footnotes (3)
- [F1]5,736 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 16,048 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms and conditions. Remaining 207,333 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 369,240 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.
- [F2]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 277,815 shares of Valeant Pharmaceuticals International, Inc. common stock for $6.12 per share.
- [F3]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 234,888 shares of Valeant Pharmaceuticals International, Inc. common stock for $13.75 per share.